Plain-English translation of NCT07555665 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a survey-based study designed to understand how hospitals in Italy are currently using molecular testing — a type of genetic analysis — to guide treatment decisions for patients with endometrial cancer (cancer of the uterus lining). Researchers want to learn whether doctors are following new guidelines that use these genetic tests to help predict which patients need additional treatment and which patients can safely avoid it.
Recent research has shown that certain genetic patterns in endometrial cancer tumors can predict how well patients will do and whether they need additional therapy. New medical guidelines now recommend using these molecular tests to guide treatment, but it's unclear whether hospitals are actually using this approach in everyday practice. This survey aims to find out what's really happening in clinical care.
You likely qualify if…
You likely don't qualify if…
Your hospital would be asked to complete a multiple-choice questionnaire about your current practices for testing and treating endometrial cancer. You would have about one month to respond to the survey, and if needed, researchers will send a reminder. There are no visits, blood draws, or other procedures involved — this is purely a survey of your hospital's practices.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Italy
Enrollment target
~264 participants
Started
November 2025
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Camilla Nero CN Camilla Nero, PhD
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.